Danaher Corporation $DHR Shares Newly Acquired by Columbus Macro LLC

Key Points

• Columbus Macro LLC acquired 23,528 Danaher shares worth approximately $5.2 million in the third quarter. Other institutions also increased or initiated positions, with institutional investors owning 79.05% of the stock.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $235.41, despite some target-price revisions.
• Danaher recently beat quarterly earnings and revenue estimates, while its collaboration with NVIDIA and planned AI-powered autonomous laboratory could support longer-term growth. Shares traded at $224.65, and the company declared a quarterly dividend of $0.40 per share.

Columbus Macro LLC purchased a new position in Danaher Corporation (NYSE:DHR - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 23,528 shares of the conglomerate's stock, valued at approximately $5,213,000.

Several other large investors also recently added to or reduced their stakes in DHR. Virginia Wealth Management Group Inc. purchased a new stake in Danaher during the 3rd quarter valued at $12,484,000. Union Savings Bank boosted its stake in Danaher by 258.6% during the third quarter. Union Savings Bank now owns 7,883 shares of the conglomerate's stock worth $1,746,000 after buying an additional 5,685 shares during the period. Elmwood Wealth Management Inc. boosted its stake in Danaher by 73.2% during the third quarter. Elmwood Wealth Management Inc. now owns 9,986 shares of the conglomerate's stock worth $2,212,000 after buying an additional 4,222 shares during the period. Essex LLC bought a new position in Danaher during the third quarter valued at $4,692,000. Finally, Cultivar Capital Inc. bought a new position in Danaher during the third quarter valued at $619,000. 79.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on DHR shares. Stifel Nicolaus reduced their target price on shares of Danaher from $260.00 to $220.00 and set a "buy" rating on the stock in a research note on Wednesday, July 22nd. Guggenheim raised their target price on shares of Danaher from $200.00 to $250.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. Royal Bank Of Canada lifted their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an "outperform" rating in a research note on Monday, October 5th. Barclays upped their price target on shares of Danaher from $230.00 to $255.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $235.41.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments

Danaher Trading Up 0.8%

Shares of NYSE:DHR traded up $1.81 during trading on Wednesday, reaching $224.65. 3,595,884 shares of the company were exchanged, compared to its average volume of 4,457,645. The business's fifty day simple moving average is $212.41 and its 200-day simple moving average is $195.13. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The firm has a market capitalization of $157.93 billion, a PE ratio of 39.90, a P/E/G ratio of 2.78 and a beta of 0.76.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher's quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 earnings per share. On average, research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher's dividend payout ratio (DPR) is presently 28.42%.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.